Pulse Biosciences (NASDAQ:PLSE) Raised to Sell at StockNews.com

Pulse Biosciences (NASDAQ:PLSE) was upgraded by equities researchers at StockNews.com to a “sell” rating in a note issued to investors on Thursday.

Pulse Biosciences Price Performance

Shares of PLSE opened at $19.63 on Thursday. Pulse Biosciences has a 1 year low of $6.59 and a 1 year high of $22.69. The company’s fifty day moving average is $18.06 and its two-hundred day moving average is $16.95.

Pulse Biosciences (NASDAQ:PLSE) last issued its earnings results on Wednesday, October 30th. The company reported ($0.21) earnings per share for the quarter. During the same quarter last year, the firm earned ($0.19) EPS.

Insider Transactions at Pulse Biosciences

In other Pulse Biosciences news, CEO Burke Thomas Barrett sold 50,000 shares of the stock in a transaction dated Wednesday, December 11th. The shares were sold at an average price of $17.42, for a total value of $871,000.00. Following the completion of the transaction, the chief executive officer now directly owns 63,172 shares of the company’s stock, valued at approximately $1,100,456.24. This trade represents a 44.18 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, Director Robert W. Duggan purchased 55,256 shares of Pulse Biosciences stock in a transaction dated Friday, December 13th. The shares were bought at an average price of $17.18 per share, with a total value of $949,298.08. Following the completion of the transaction, the director now owns 42,328,717 shares in the company, valued at approximately $727,207,358.06. This trade represents a 0.13 % increase in their position. The disclosure for this purchase can be found here. Company insiders own 71.50% of the company’s stock.

Institutional Investors Weigh In On Pulse Biosciences

Several institutional investors and hedge funds have recently made changes to their positions in the business. Charles Schwab Investment Management Inc. raised its position in Pulse Biosciences by 193.0% during the third quarter. Charles Schwab Investment Management Inc. now owns 148,114 shares of the company’s stock worth $2,598,000 after acquiring an additional 97,565 shares during the last quarter. State Street Corp increased its stake in shares of Pulse Biosciences by 17.8% during the 3rd quarter. State Street Corp now owns 461,333 shares of the company’s stock worth $8,092,000 after purchasing an additional 69,696 shares in the last quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC acquired a new position in shares of Pulse Biosciences during the 3rd quarter worth approximately $588,000. Geode Capital Management LLC lifted its stake in Pulse Biosciences by 7.8% in the 3rd quarter. Geode Capital Management LLC now owns 457,165 shares of the company’s stock valued at $8,020,000 after buying an additional 33,200 shares in the last quarter. Finally, Barclays PLC grew its holdings in Pulse Biosciences by 361.4% during the 3rd quarter. Barclays PLC now owns 30,306 shares of the company’s stock valued at $530,000 after buying an additional 23,738 shares during the last quarter. 76.95% of the stock is currently owned by hedge funds and other institutional investors.

About Pulse Biosciences

Pulse Biosciences, Inc operates as a novel bioelectric medicine company. The company offers CellFX System, a tunable, software-enabled, and console-based platform that delivers nano second duration pulses of electrical energy to non-thermally clear targeted cells while sparing adjacent non-cellular tissue to treat a various medical condition by using its Nano-Pulse Stimulation technology.